BioTech Stocks Today | CYTX | INO | GENE | REGN | MNKD

1

BioTech Stocks To Watch TodayCytori (CYTX) Stocks Continue To Climb Following Poor Earnings

I’ve always found it interesting when a company produces a poor earnings report, but their stocks react in a positive way. For instance, look at Amazon for the life of its performance in the stock market! Nonetheless, Cytori (CYTX) seems to be capable of doing just that. After producing a report that showed a loss of $0.08 per share, the stock fell 9% before making a dramatic recovery to close the day Friday in the green. The end of day upward momentum we saw Friday seems to be carrying through to today. Currently (1:03) the Cytori (CYTX) stocks are trading for $1.33 after gaining 10.82% so far today!

Outlook – While I’m not personally willing to join the frenzy with the company producing a loss, it’s obvious that the stock gained a bit of momentum; which will most likely carry through at least the rest of the day.

Inovio Pharmaceuticals (INO) Stocks Soar On Slightly Positive Earnings Report

Here’s another company that despite producing losses, is soaring in the stock market today. Inovio Pharmaceuticals (INO) recently provided their Q4 and year end earnings report; and I didn’t find much positive about it. In the quarter, the company produced a loss of more than $7 million. While the loss is much less than the loss the company took the year before, it’s still a loss; and in my humble opinion, losses are bad. Nonetheless, the company’s stock is climbing dramatically. After a gain of 18.18% so far today (1:10), the stock is trading at $8.32 per share.

Outlook – This is another one where the upward momentum is definitely exciting, but I think I’d resist the urge to buy. As an investor, I’m most excited when a company shows high potential for long term growth. The bottom line is that a company cannot survive on losses for very long (a few years, maybe, but not much longer than that). Therefore, until Inovio Pharmaceuticals (INO) starts to produce profits, I’d personally stay away.

Genetic Technologies (GENE) Stocks Aren’t Sure Where To Go

After struggling through share dilution last week as a result of successful fund raising, investors in Genetic Technologies (GENE) are hoping for a recovery this week. However, it seems as though the stock price is confused as to where to go. This is most likely the result of investors waiting to make sure that downtrends are over and growth can start again. Nonetheless, the stock is currently (1:16) trading at $4.50 per share after losing 4.46% so far today through a series of dramatic ups and downs.

Outlook – Call me an optimist, but I still think that Genetic Technologies (GENE) is going to end the week in the green. I think the effects of share dilution are over and it’s time for investors to start feeling comfortable with the stock again this week.

Regeneron Pharmaceuticals (REGN) Stock Is Showing Impressive Growth

So far today, Regeneron Pharmaceuticals (REGN) is showing incredibly impressive growth; currently trading in all-time high territory. Following an incredible month, I think what we’re seeing here is the beginning of a relatively long-term uptrend! Currently (1:22) the company’s stock is trading at $446.92 per share after gaining 4.08% so far today.

Outlook – This one is obvious. Regeneron Pharmaceuticals (REGN) stocks have been soaring in value recently and are show.

MannKind (MNKD) Continues To Struggle To Gain Momentum

This one is very upsetting. MannKind (MNKD) is a great company, with great new products that wasn’t given a fair shake in the most recent analysis of the stock by Goldman Sachs. As a result, Goldman Sachs downgraded the company’s stock in a move that has been viewed as controversial to say the least. While I’m expecting to see somewhat of a recovery throughout the week, the stock is down so far today. Currently (1:26), MannKind (MNKD) stocks are trading at $5.47 per share after falling 0.73% so far today.

Oultook – As mentioned above, MannKind (MNKD) is a great company with great products, and in my opinion, it’s slated for growth. Although the stock does seem to be a bit confused today, I think we’re going to see positive movement overall today as more and more investors start to forget the unfounded Goldman Sachs downgrade.

What Do You Think?

Where do you think the stocks mentioned here are headed? Let us know in the comments below!

Image Credit

1 COMMENT

  1. I have owned mnkd for 4 years and watched it go through all the steps necessary to take the drug to market. I believe that it is a game changer. in the long term it has great potential, in the near term because about 30% of the shares are sold short the potential for a short squeeze bounce makes me giddy, just saying.

LEAVE A REPLY

Please enter your comment!
Please enter your name here